Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 5,775 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bronchial Disease Clear all
Recruiting Phase 1 Interventional

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

NCT06835569
View directory record Official record
Conditions
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer), Advanced Solid Tumors
Interventions
ALTA3263, cetuximab, mFOLFOX6, Pembrolizumab, Pemetrexed + Cisplatin /Carboplatin, mFOLFIRINOX, GnP, Midazolam
Drug
Lead sponsor
Alterome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 25, 2026, 9:48 AM EDT
Completed Phase 2 Interventional Results available

Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery

NCT00551369
View directory record Official record
Conditions
Lung Cancer
Interventions
SBRT
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
19
States / cities
Birmingham, Alabama • Berkeley, California • Carmichael, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 25, 2026, 9:48 AM EDT
Completed No phase listed Observational

TS Overexpression in SCLC: Mechanism and Therapeutic Targeting

NCT03741829
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 25, 2026, 9:48 AM EDT
Completed Phase 1 Interventional

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

NCT02635672
View directory record Official record
Conditions
Neoplasms
Interventions
VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, VIP152 (BAY 1251152) 15 mg
Drug
Lead sponsor
Vincerx Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
13
States / cities
Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 25, 2026, 9:48 AM EDT
Completed Phase 1Phase 2 Interventional

VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer

NCT03268057
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
VX15/2503 + avelumab
Drug
Lead sponsor
Vaccinex Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
11
States / cities
Fayetteville, Arkansas • Los Angeles, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 25, 2026, 9:48 AM EDT
Recruiting No phase listed Observational

DESTINY-PANTUMOUR04

NCT07124000
View directory record Official record
Conditions
Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer
Interventions
Trastuzumab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 9:48 AM EDT
Recruiting Phase 1 Interventional

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

NCT06598306
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
Tarlatamab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 25, 2026, 9:48 AM EDT
Completed Phase 1 Interventional Results available

A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

NCT01283516
View directory record Official record
Conditions
Tumors Characterized by Genetic Abnormalities of ALK
Interventions
LDK378
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 25, 2026, 9:48 AM EDT
Completed Phase 2 Interventional Results available

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban

NCT03326063
View directory record Official record
Conditions
Nasal Polyps, Asthma, Aspirin-Induced, Aspirin-exacerbated Respiratory Disease, Aspirin-Sensitive Asthma With Nasal Polyps
Interventions
Ifetroban, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 25, 2026, 9:48 AM EDT
Terminated Phase 2 Interventional Results available

Inhaled Corticosteroids Versus Observation for Patients With Decreased Lung Function Status

NCT00656916
View directory record Official record
Conditions
Bronchiolitis
Interventions
Fluticasone Propionate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Oct 25, 2026, 9:48 AM EDT
Recruiting Phase 2 Interventional

Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer

NCT07216404
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Unipolar Depression
Interventions
Biospecimen Collection, Counseling, Interview, Psilocybin, Survey Administration
Procedure · Other · Drug
Lead sponsor
Alan Davis
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 25, 2026, 9:48 AM EDT
Recruiting Phase 1Phase 2 Interventional

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

NCT03556228
View directory record Official record
Conditions
Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Mesothelioma, Esophageal Cancer, Any Solid Tumors Progressed After a Prior Immunotherapy, Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC, Salivary Gland Carcinomas, Head and Neck Cancers - Salivary Gland, Head and Neck Cancers - Nasopharyngeal, Head and Neck Cancers - Throat, Small Cell Lung Cancer ( SCLC ), Lung Cancer (Locally Advanced or Metastatic), Head and Neck Cancers - Tonsils, Head and Neck Cancers Hypopharynx, Head and Neck Cancers Larynx, Head and Neck Cancers Lip, Head and Neck Cancers Nasopharynx, Head and Neck Cancers Oral Cavity, Head and Neck Cancers, Head and Neck Cancers Oropharynx, Head and Neck Cancers Trachea
Interventions
VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
Drug
Lead sponsor
VM Oncology, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
14
States / cities
Santa Rosa, California • Hartford, Connecticut • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 25, 2026, 9:48 AM EDT
Terminated Not applicable Interventional

Effects of Behavioral Interventions on Mechanisms of Pain Regulation and Hedonic Regulation

NCT02935465
View directory record Official record
Conditions
Chronic, Non-neuropathic Back Pain
Interventions
Mindfulness-Oriented Recovery Enhancement (MORE), Support Group
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
21 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 25, 2026, 9:48 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma

NCT02443298
View directory record Official record
Conditions
Asthma
Interventions
placebo, risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
20
States / cities
Costa Mesa, California • Mountain View, California • Centennial, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 25, 2026, 9:48 AM EDT
Completed No phase listed Observational

Detection of Early Metastases in Patients With Stage I Non-small Cell Lung Cancer

NCT00003006
View directory record Official record
Conditions
Lung Cancer
Interventions
reverse transcriptase-polymerase chain reaction, immunohistochemistry staining method
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
10
States / cities
Iowa City, Iowa • Baltimore, Maryland • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Oct 25, 2026, 9:48 AM EDT
Recruiting Phase 1 Interventional

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

NCT05245500
View directory record Official record
Conditions
Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor, Pancreatic Adenocarcinoma, Advanced Solid Tumor
Interventions
MRTX1719
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • Lone Tree, Colorado • Jacksonville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 25, 2026, 9:48 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers

NCT02838836
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Hepatocellular Cancer, Colorectal Cancer
Interventions
Study sample collection
Procedure
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
620 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 25, 2026, 9:48 AM EDT
Completed No phase listed Observational

Studying Tumor Tissue Samples From Patients With Early-Stage Non-Small Cell Lung Cancer

NCT01517971
View directory record Official record
Conditions
Lung Cancer
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 25, 2026, 9:48 AM EDT
Completed No phase listed Observational

Study to Evaluate the Effects of Weight Loss on Airway Inflammation and Mechanics in Subjects With Asthma (Asthma-Bariatric Surgery Study)

NCT00615498
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Oct 25, 2026, 9:48 AM EDT
Terminated Phase 3 Interventional Results available

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

NCT02654587
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
OSE2101, Docetaxel, Pemetrexed
Biological · Drug
Lead sponsor
OSE Immunotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Burbank, California • Washington D.C., District of Columbia • Boca Raton, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 25, 2026, 9:48 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies

NCT00445198
View directory record Official record
Conditions
Small Cell Lung Cancer, Small Cell Lung Carcinoma
Interventions
ABT-263
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
14
States / cities
Peoria, Arizona • Phoenix, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 25, 2026, 9:48 AM EDT
Completed Phase 3 Interventional Results available

Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP Study

NCT03306992
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Secondary Lung Cancer
Interventions
Personalized Exercise Program
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 25, 2026, 9:48 AM EDT
Completed Phase 2 Interventional Results available

Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

NCT00467844
View directory record Official record
Conditions
Cachexia
Interventions
GTx-024, Placebo
Drug
Lead sponsor
GTx
Industry
Eligibility
Not listed
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
50
States / cities
Anchorage, Alaska • Fayetteville, Arkansas • Corona, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 25, 2026, 9:48 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder

NCT00621946
View directory record Official record
Conditions
Severe Asthma, Moderate or Severe Major Depressive Disorder
Interventions
Placebo, Escitalopram
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 25, 2026, 9:48 AM EDT